Buscar Co Stock Price, News & Analysis

Buscar Company (OTC: CGLD) announced progress in its audit with Barton CPA PLLC and steps toward becoming a fully reporting SEC issuer and uplisting to the OTCQX Market. The company filed fiscal year financial statements for the period ended June 30, 2025 on OTC Markets in August and says auditors led by Dan Barton have advanced key audit reviews. Management retained SEC counsel and plans a Form 10 submission to enhance transparency, investor access, and shareholder liquidity while noting forward-looking risks such as audit delays and SEC compliance challenges.

Buscar Company (OTC: CGLD) announced completion of an independent NI 43-101 technical report (effective October 2025) for its Treasure Canyon, California project prepared by Dr. Abe Beagles of Mother Lode Mining.

The report cites Proven Reserves with an estimated gross in-situ mineralized value of approximately $34.55 billion based on certified multi-element assays (gold, silver, platinum-group metals, and rare earth elements). The deposit includes a continuous alluvial channel averaging 51 feet depth across a 200-acre site and verified lower-grade domains.

Metallurgical testing shows >b>92% recovery via reagent-free gravity concentration; proprietary Plasma Extractor System (PES) is noted for recovering monoatomic/colloidal gold. The report identifies REE targets (scandium, yttrium, lanthanum) and highlights potential alignment with U.S. critical-minerals initiatives and government collaboration. Environmental reclamation and zero-discharge processes are emphasized.

Buscar Company (OTC: CGLD) announced completion of an independent NI 43-101 Technical Report for the Treasure Canyon Gold Mine (Plumas County, CA), effective October 2025. The report cites a combined gross in-situ value of ~$117.16 billion across Proven and Probable reserves, based on multi-element assays (gold, silver, PGM, rare earths).

Key metrics: continuous alluvial channel over 200 acres, 51 ft average depth, 24.68 million tons mineralized mass (bulk density 1.5 t/yd3), Proven reserves valued at $34.55B, Probable at $82.61B, and estimated recoverable reserves of 81,200 ounces after a 92% recovery. Startup capital estimated $1.25M, annual OPEX $590,000, and pre-tax margins >35% at 2025 metal prices.

Buscar Company (OTC:CGLD) announced the appointment of Eric Sauer as Chief Operating Officer of its subsidiary Armorgenix, where Buscar holds a 70% stake acquired in June 2025. Sauer brings over 40 years of experience in pharmacy, naturopathy, and holistic medicine.

Sauer will oversee operations, strategic planning, and expansion of Armorgenix's manufacturing capabilities, including a planned Texas facility. The appointment strengthens Buscar's diversified portfolio, which includes Eon Discovery Inc. (gold mining operations) and a 50% stake in Terramer Inc. (hemp-based bioplastics). Armorgenix focuses on enzyme-based therapies, natural remedies, and detoxification solutions, targeting the U.S. pharmaceutical market projected to reach $854.83 billion in 2025.

Buscar Company (OTC:CGLD) has announced significant progress in its journey toward becoming a fully reporting SEC company and uplisting to the OTCQX Market. The company has successfully filed its fiscal year financial statements for the period ended June 30, 2025, on OTC Markets.

Under CEO Alexander Dekhtyar's leadership, Buscar is advancing its audit process with Barton CPA PLLC, a PCAOB-registered firm, in preparation for filing a Form 10 with the SEC. The company's commitment to transparency and regulatory compliance demonstrates its strategic focus on enhancing investor confidence and market visibility.

Buscar Company (OTC: CGLD), a diversified holding company, has announced significant steps toward achieving fully reporting status with the SEC and uplisting to the OTCQX Market. The company has engaged Barton CPA PLLC, a PCAOB-registered firm, to conduct a comprehensive audit and retained specialized SEC legal counsel to prepare and file a Form 10. Led by CEO Alexander Dekhtyar, Buscar operates across natural resources, sustainable technologies, and pharmaceuticals through its subsidiaries: Eon Discovery Inc. (gold mining), Terramer Inc. (biodegradable bioplastics), and Armorgenix (pharmaceuticals). The company's strategic initiatives aim to enhance transparency, meet OTCQX's stringent financial standards, and improve shareholder value through increased market visibility and liquidity.

Buscar Company (CGLD) has formed a strategic partnership with Mother Lode Mining to develop the Treasure Canyon Gold Mine in Plumas County, California. The 200-acre site contains an estimated 3.58 million troy ounces of gold equivalent, valued at $11.99 billion at current gold prices ($3,350/oz). Dr. John Beagles from Mother Lode Mining is leading the preparation of NI 43-101 and SEC SK-1300 reports, expected in Q3 2025, and is developing a Plasma Extractor System that could increase gold recovery by 3-10x. A geological report by Mars Mines Ltd has reclassified the deposits as Iron Oxide Copper-Gold (IOCG), suggesting significant potential for gold, copper, and other valuable metals. On-site work is scheduled to begin in mid-July 2025.

Buscar Company (OTC: CGLD) has acquired a 70% stake in Armorgenix Company through a strategic stock swap, marking its expansion into the pharmaceutical sector. Armorgenix specializes in detoxification and antiviral solutions, including its DetoxShield product. The acquisition follows Buscar's recent 50% stake in Terramer Inc. and complements its existing portfolio, which includes Eon Discovery's gold mining operations. Armorgenix plans to establish a Texas-based manufacturing facility and Wyoming-based corporation within 24-36 months. The acquisition positions Buscar in the growing U.S. antiviral market, valued at $22.2 billion in 2024, with projections showing the global market reaching $85.4 billion by 2034. The broader U.S. pharmaceutical market is expected to grow from $854.83 billion in 2025 to $1,447.20 billion by 2032, with a CAGR of 7.8%. The deal strengthens Buscar's diversified portfolio, combining pharmaceutical innovation with sustainable technologies and natural resources.

Buscar Company (OTC: CGLD) has acquired a 50% stake in Terramer, Inc. through a stock swap transaction. Terramer is known for developing TERBO-1000, a hemp-based bioplastic that biodegrades within 180 days without leaving microplastic residue.

Terramer operates a 350,000 sq. ft. facility capable of producing 300 million pounds annually. The company has secured $6.8 million in purchase orders and over $80 million in LOIs from major household brands. The partnership aims to accelerate TERBO-1000's development and commercialization across packaging, food service, automotive, and construction industries.

The deal structure involves Buscar issuing shares to Terramer stakeholders for the 50% equity position, preserving cash while aligning both companies' interests. This acquisition complements Buscar's portfolio, which has recently benefited from a 70% surge in gold prices affecting its mining assets.